Halberd Collaborates With GreenBioAZ, Inc. For the Development of Its Patent Pending Radio Frequency Technology to Eliminate Disease Pathogens

By |2021-02-15T21:23:39-05:00February 16th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, February 16, 2021 – Halberd Corp. (OTC PINK:HALB) has engaged GreenBioAZ, Inc. to conduct laboratory testing of Halberd’s patent pending Radio Frequency (RF) extracorporeal treatment to eliminate infectious disease pathogens.  The methodology entails treating bodily fluids with an Antibody-Metallic Moiety Conjugate (AMMC) which targets a specific pathogen such as SARS-CoV-2 during extracorporeally ...